Global Omalizumab Monoclonal Antibody Biosimilars Market 2026 – 2035

Market Overview

The worldwide omalizumab monoclonal antibody biosimilars market size was approximately USD 1.82 billion in 2025 and is expected to reach approximately USD 2.06 billion in 2026 and will grow to nearly USD 6.40 billion by 2035 and will witness a CAGR of 13.39% between the forecast period of 2026 and 2035. This market is anticipated to gain momentum due to rising demand for affordable biological therapies and the expiry of major patents on originator omalizumab products.

With the increased incidence of allergic asthma, chronic urticaria, and other immunological conditions the demand for target therapies is growing rapidly. Increased adoption rate of biosimilars by healthcare providers and patients is being favored by conducive regulatory policies. Expanded accessibility of healthcare along with payer insistence on a cut in treatment expenditure further supplements demand. Advancements in biologics manufacturing and intensifying competition from biosimilar manufacturers would augment the market growth over the long run.

Impact of US-Iran War on the Omalizumab Monoclonal Antibody Biosimilars Market

The supply chain of raw materials, including cell culture media, recombinant proteins, single-use bioreactor bags, purification resins, and glass vials required to produce omalizumab monoclonal antibody biosimilars has been impacted by the US-Iran war. Increasing crude oil prices and geopolitical instability in the Middle East have caused the increase in costs associated with petrochemical-derived plastic components (e.g., tubing, filters, storage bags), chromatography resins, and cold chain logistics, thus affecting the pricing of omalizumab biosimilars.

Furthermore, disruptions to global shipping routes, particularly through the Strait of Hormuz, have delayed the delivery of temperature-sensitive raw materials and finished drug products between manufacturing sites (primarily in Europe, India, and China) and key markets (North America, the EU, and Asia-Pacific), impacting inventory and supply reliability.   

Market Highlight

• In 2025, the region of North America dominated the omalizumab monoclonal antibody biosimilars market and held around 40.40% share in the total market due to favorable biopharmaceutical adoption, well-developed healthcare infrastructure, and sound reimbursement policies.

• The Asia Pacific is predicted to witness the fastest CAGR of around 13.6% over the forecast period 2026-2035, driven by an increase in the prevalence of allergic disorders, development in the manufacturing of biosimilars, and the rising penetration of innovative biological treatments.

• In 2025, the subcutaneous injection segment occupied more than 45.5% market share of the market by product type due to convenient administration, high patient compliance, and wide usage in asthma and chronic urticaria treatment.

• By product type, the intravenous injection segment is likely to observe a CAGR of around 43.5% over the period 2026-2035. This growth is mainly due to its usage in hospital settings which need carefully controlled and precise drug delivery.

• The asthma segment was the dominant application in 2025 and held around 44.5% of the market share, whereas chronic idiopathic urticaria is expected to witness the highest CAGR of 14.0% during the forecast period due to unmet treatment needs and increasing biologics penetration.

• Hospital pharmacies held almost 54.6% of the market share in 2025 by distribution channel because biological treatments require supervision, while the online pharmacies are expected to rise with the fastest CAGR in terms of increasing digital healthcare adoption and the convenience of home delivery.

Significant Growth Factors

Serious growth potentials exist in the Market Trends of the Omalizumab Monoclonal Antibody Biosimilars for the following reasons:

• Patent Expiration and the Increasing Uptake of Biosimilars: The expiration of exclusivity of the reference biologic (omalizumab) will accelerate the entry of biosimilars. Healthcare systems are encouraging the use of biosimilars to lower treatment costs and increase the availability of biologic medicines, which will further drive physicians and payers towards adopting the cost-effective alternative for long-term treatment of chronic diseases such as asthma and chronic urticaria. An increased adoption of biosimilars will bring about both expanded reach for patients and an alleviated financial burden on healthcare systems.

• ·Rising Incidence of Allergic and Respiratory Diseases: The increasing prevalence of Asthma, Allergic Rhinitis, and Chronic Spontaneous Urticaria in the population are major drivers for the increased use of omalizumab based treatments. Air pollution, urbanization, and lifestyle changes are a few contributing factors for the rising incidence of the disease on a global scale. As the disease spreads globally, the cost-effectiveness of biologic treatments will further push for the adoption of biosimilars both in the developed countries and in emerging economies.

• Constant Pressure to Contain Healthcare Costs: The mounting need for cost containment among the government and insurance providers is driving the need to curtail the use of expensive biologic treatments, especially when an alternative such as a biosimilar exists. This will be one of the biggest growth drivers in the Omalizumab Biosimilars market across different regions. Increased pressure will ensure the adoption of biosimilars in tender based procurement systems and in reimbursements favoring biosimilars.

• Improvement in Biologics Manufacturing and regulatory support: Rapid advancements in the biologics manufacturing technologies are enabling pharmaceutical companies to efficiently and cost-effectively produce high quality biosimilars. Stringent approval guidelines and pathways for biosimilar development from regulatory authorities such as the FDA and EMA, along with a growing clarity on the concept of interchangeability, are expected to make it easier and faster to get biosimilars approved, thereby fostering increased competition and innovation in the Market.

What are the Significant Developments that are Powering up the Omalizumab Monoclonal Antibody Biosimilars Market today?

• Advances in Biologics Manufacturing and Analytical Characterization: Key progress has been made in biologics manufacturing technologies and analytical methods which allow the highly similar omalizumab biosimilar to Reference Product. Developments in cell line engineering, purification technologies, and real time monitoring of quality have been boosting up consistency and scalability. Meanwhile, the growing advanced characterization methods (such as structural and functional comparability studies) have been facilitating the regulatory confidence and approvals of biosimilars, leading to rapid market entry and wider commercialization.

• Broaden of Biosimilar Development Pipelines and Clinical Programs: The pipelines for omalizumab biosimilars are currently robust with increasing investment from global and biotech companies, and many ongoing clinical trials are aimed to demonstrate equivalence in terms of efficacy, safety and immunogenicity in multiple indications including asthma and chronic urticaria. This broadening of development programs has resulted in intensifying competition, increasing product availability, and leading to decreased price, which in turn enables the patient's access to the biologic therapy.

• Streamlined Regulatory Approaches and Interchangeability Guidelines: An ongoing trend in the biosimilar markets is the establishment of clear and straightforward approval pathways for biosimilars by regulatory agencies, with increasing use of guidelines in interchangeability and indication extrapolation to reduce the development burden and clinical practice implementation. Furthermore, evolving regulations on substitution and physician prescribing practice would contribute to promoting the widespread use of biosimilars.

• Strategic Collaborations and Market Access Activities: The market witnesses increasing partnerships, licensing agreements, and co-development agreements which aim to enhance the presence of manufacturers in the biosimilar market. Collaborations between multinational corporations and regional biopharmaceutical companies provide superior manufacturing capacity and greater geographic penetration. Concurrently, investments in the marketing strategies, payer outreach, and distribution systems enable extensive access of omalizumab biosimilars across developing and developed markets.

Category Wise Insights

By Product Type

Why Subcutaneous Injection leads the market?

Subcutaneous injection dominates the omalizumab monoclonal antibody biosimilars market as it has proven clinical usage, is more convenient to administer, and is highly accepted by the patients. Subcutaneous injection is commonly prescribed for chronic diseases like asthma and urticaria and can also be self-administered at home in some cases. Prefilled syringes and autoinjectors make the drug administration simpler and easier for both healthcare providers and the patients. Extensive clinical validations and familiar use among the physicians contribute to its growing market dominance.

Intravenous injection dominated a small but important part of the market. It is used for clinical studies and for delivering the medication when prompt response and precise dosing are necessary. Further strengthening the dominance of subcutaneous administration are advancements in administration devices and patient-convenient formulation of the biosimilars.

By Application

Why Asthma dominates the market?

Asthma dominated the omalizumab biosimilars market due to the high worldwide prevalence of moderate-to-severe allergic asthma and the proven effectiveness of anti-IgE therapy. The treatment with an omalizumab-based drug is recommended for asthma patients who are not appropriately controlled by standard therapies and plays a vital role in the treatment strategy of complex asthmatic patients. Higher diagnosis rates and the long term duration required for the treatment have kept the demand steady over the years.

Chronic idiopathic urticaria is the fastest growing segment due to increasing awareness and demand for biological treatments in patients unresponsive to antihistamines. Other applications like nasal polyps and other allergic conditions are steadily growing with an increase in its clinical applicability and extensive research for further applications of omalizumab based drugs.

By Distribution Channel

Why Hospital Pharmacies dominate the market?

Hospital pharmacies dominate the omalizumab monoclonal antibody biosimilars market due to specialized treatment needed and the need for professional supervision. Hospitals are the major center for initial diagnosis, prescription and dosage for severe allergic conditions. Efficient procurement systems and support of reimbursement have maintained the leading position of hospital pharmacies over the others.

Online pharmacies show the highest growth rate, owing to rising digital healthcare access, improving reach of specialty drugs and ease of home delivery. Retail pharmacies also hold an important share of the market in continued medication management whereas other channels are contributing toward accessibility across different patient groups.

Report Scope

Regional Analysis

Why Asia Pacific Will Dominates the market in 2025?

Asia Pacific will dominate the omalizumab monoclonal antibody biosimilars market due to a high volume of asthma and allergy disorder patient populations and better accessibility to biologic treatments. Several countries in the Asia Pacific, such as China, India, and South Korea have shown an upward trend in healthcare spending and developing biologic manufacturing capabilities. Government policies aiming at the availability of biologics at a more affordable rate and the presence of established domestic players in the biopharmaceutical industry would ensure quick market penetration. Rising diagnosis rates, awareness, and proper reimbursement policies in the Asia Pacific region are further contributing towards an increase in demand and hence the growing dominance of the Asia Pacific in the omalizumab monoclonal antibody biosimilar market.

Market Trends for China

China is expected to gain a major market share driven by the rapid growth of the Chinese biopharmaceutical sector along with increased investment in the development of monoclonal antibodies. Domestic players are focusing on developing clinical pipelines and building their capacity for producing monoclonal antibodies, while at the same time government policies aimed at a rapid approval process for drugs along with a focus on developing domestic products are driving increased biosimilar adoption. Increasing number of respiratory and allergy disorder patients in China, coupled with improved healthcare infrastructure and an expanding pharmaceutical market, has been a major driver for the demand for omalizumab monoclonal antibody biosimilars.

What is the reason behind slow but steady growth in the North America region?

The slow but steady growth in the North America region is driven by a high level of biologic usage coupled with growing acceptance of biosimilars as a cost-effective alternative therapy. Advanced healthcare system, a proper reimbursement mechanism and growing cost pressures for managing biologics have boosted the demand for biosimilars. Growing acceptance in the physicians for the usage of biologics and an established process for the regulatory approval of biosimilars will continue to be drivers for market growth. Increasing number of severe asthma patients and chronic urticaria in the North American region, coupled with its early adoption of biologics is expected to provide stable demand in the long run.

Market Size for the U.S

In the U.S., the omalizumab monoclonal antibody biosimilars market is valued at USD 0.60 Billion in 2025 and is expected to grow at a CAGR of 13.57% during the forecast period of 2026-2035.

U.S. Market Trends

The U.S. Market is driven by an increased number of approvals of omalizumab monoclonal antibody biosimilars, along with the strong payor-driven adoption strategies focused on cost containment of biologics. Healthcare organizations and insurance providers across the nation are pushing for the adoption of biosimilars in order to lower the high treatment cost for biologics. Strong evidence that highlights the comparable efficacy and safety profiles of omalizumab monoclonal antibody biosimilars as compared to their reference drugs along with better awareness in physician circles will be driving the market growth in the U.S. Strategic collaborations between pharmaceutical firms, as well as its wide distribution network are expected to contribute positively.

What is the reason for Europe implementing cost-efficiency and biosimil adoption?

The European market is being driven by the early adoption of biosimilars along with a strong emphasis on adopting the cost-efficiency measure. The governments across Europe are encouraging the use of biologics at an economical price, driven by price controls, tenders, and substitution rules, to the benefit of the patient. Increasing awareness among healthcare professionals and patients coupled with favorable market dynamics in terms of price, along with healthcare expenditure concerns, will drive the market for omalizumab monoclonal antibody biosimilars in the long run in Europe.

Market Trends for Germany

Germany is playing a significant role in Europe for the omalizumab monoclonal antibody biosimilar market, owing to a mature biosimilar regulatory framework and a well-developed healthcare system that emphasizes high doctor acceptance. Increasing utilization of biologic drugs for the treatment of asthma and allergy-related disorders along with tight control over healthcare costs in Germany, coupled with its early adoption of biosimilars is providing support to a sustained growth of the market.

What is the reason for Middle East & Africa region's growth?

The growth in the Middle East & Africa region for omalizumab monoclonal antibody biosimilars is being supported by an improving healthcare system and growing awareness about the advanced biologic treatments in this region. The governments are striving to increase the availability of effective and low-cost drugs for their patient population and there has been a significant increase in investment in the healthcare infrastructure as well as collaborations between the global pharma players and the local ones. Though still in an early stage of adoption, consistent demand from the region will boost a steady growth in the years to come.

Top Players in the Market and Their Offerings

• Roche Holding AG

• Novartis AG

• Teva Pharmaceutical Industries Ltd.

• Mylan N.V.

• Pfizer Inc.

• Amgen Inc.

• Samsung Bioepis Co. Ltd.

• Celltrion Healthcare Co. Ltd.

• Biocon Limited

• Sandoz International GmbH

• Dr. Reddy's Laboratories Ltd.

• Fresenius Kabi AG

• Stada Arzneimittel AG

• Coherus BioSciences Inc.

• Apotex Inc.

• Hoffmann-La Roche Ltd.

• Merck & Co. Inc.

• Lupin Limited

• Zydus Cadila

• Intas Pharmaceuticals Ltd.

• Others

Key Developments

Market has grown with the participants in the industry taking efforts to expand their activities & enhance their product basket.

• Samsung Bioepis filed an omalizumab biosimilar BLA with the US FDA and was given a CRL in February 2026, to resubmit it in the third quarter of 2026.

• Celltrion Healthcare's top-line results were released in fourth quarter 2025 which indicates that the omalizumab biosimilar, CT-P39 has met the primary endpoint and is also able to deliver similar IgE suppression as compared to the reference. Also showed enhanced lung function. A planned submission to the FDA & EMA.

• Biocon Limited & Sandoz entered a co-promotion partnership for Biocon's omalizumab biosimilar to be marketed and sold in Germany, France, and the U.K. (market); the launch is scheduled for the first quarter of 2026.

These types of strategies have enabled players to firm their position in the market, bring innovative products into the market, and ride on a global trend towards more disposable and less invasive surgical procedures.

The Omalizumab Monoclonal Antibody Biosimilars Market is segmented as follows:

By Product Type

• Subcutaneous Injection

• Intravenous Injection

By Application

• Asthma

• Chronic Idiopathic Urticaria

• Nasal Polyps

• Others

By Distribution Channel

• Hospital Pharmacies

• Retail Pharmacies

• Online Pharmacies

• Others

Regional Coverage:

North America

• U.S.

• Canada

• Mexico

• Rest of North America 

Europe

• Germany

• France

• U.K.

• Russia

• Italy

• Spain

• Netherlands

• Rest of Europe

Asia Pacific

• China

• Japan

• India

• New Zealand

• Australia

• South Korea

• Taiwan

• Rest of Asia Pacific 

The Middle East & Africa

• Saudi Arabia

• UAE

• Egypt

• Kuwait

• South Africa

• Rest of the Middle East & Africa

Latin America

• Brazil

• Argentina

• Rest of Latin America